Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in novartis

Novartis Says Beovu Matched Rival Eylea In Visual Acuity In Eye Disease

"This data confirms our strong belief in Beovu as a potential therapy for DME patients," said Dirk Sauer, who leads Novartis Pharma Ophthalmology's drug development.

Read More

Roche Studies Ocrevus, Experimental Drug In MS As Novartis Moves In

Roche has started a late-stage clinical trial for its molecule fenebrutinib and is doing a clinical trial of higher-dose Ocrevus against relapsing MS and primary progressive MS.

Read More

Novartis Immuno-Oncology Drug Candidate Fails Skin Cancer Trial

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Read More

Novartis To Provide 'No Profit' COVID-19 Drugs To Low-Income Countries

Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank's list of low- and lower-middle income nations.

Read More

Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal

Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Read More

Novartis, Former Unit To Pay $346 Million To Resolve US Bribery Charges

Novartis will also pay $112.8 million to settle related civil charges by the U.S. Securities and Exchange Commission.

Read More

Novartis CEO Says Any New Coronavirus Vaccine Will Take Two Years

But experts have said no vaccine is expected to be ready for use until at least 2021, as they must be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.

Read More

Novartis Wins Expanded European OK For Cosentyx Amid Pursuit Of $5 Billion Sales

European Commission (EC) approved Cosentyx for adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA), characterized by chronic back pain.

Read More

Novartis Posts First-Quarter Sales, Profit Beat As COVID-19 Spurs Prescriptions

Sales rose to $12.3 billion from $11.1 billion in the year-ago period, also above the poll average of $12 billion

Read More

Novartis To Sponsor Large Clinical Trial Of HCQ In Hospitalised COVID-19 Patients

Novartis plans to begin enrollment for this study within the next few weeks and is committed to reporting results as soon as possible.

Read More

Aurobindo Pharma's $1 Billion Deal With Novartis Unit Sandoz Collapses

This decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines

Read More

Novartis Scraps Sale Of Assets To Aurobindo Pharma After Failing To Get FTC Nod

Novartis said it would sell the assets for up to $1 billion to Aurobindo under Chief Executive Officer Vas Narasimhan's plans to reshape the drugmaker.

Read More

Novartis Works With Life Sciences Companies To Fight Covid-19

Fifteen companies have agreed to share their libraries of compounds that already have some degree of safety and activity data.

Read More

Novartis Sees No Coronavirus Disruption Amid China Growth

Cosentyx's sales for the 12-month period rose 28% to $3.6 billion, heart drug Entresto was up 71% to $1.7 billion and Zolgensma for spinal muscular atrophy hit $361 million.

Read More

Sanofi Poised To Appoint Novartis' Hudson As CEO

Hudson has been chosen because of his reputation. He is known as a solid manager and has an expertise in digital relating to pharmaceuticals

Read More